Pfizer has now announced that it intends to sell Comirnaty for between $110 and $130 per dose – roughly four times the current price, and 100 times The People’s Vaccine Alliance’s estimated ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...

In this note, while we briefly touch upon Pfizer’s performance in 2024, we focus on the impact on PFE stock and how 2025 ...

General side effects: tiredness, headache, muscle pain, chills, joint pain, fever, nausea, feeling unwell, swollen lymph ...

Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirnaty.

Then, this is the segment with the strongest focus in Pfizer's pipeline. If we take a look at the top 10 products in 2023, the ranking is still led by Comirnaty (19% weight), despite the drop in ...

Valued at a market cap of $152.2 billion, Pfizer Inc. (PFE) is a global biopharmaceutical company dedicated to advancing healthcare through discovering, developing, manufacturing, and distributing ...

A woman with a rare genetic disorder found unresponsive in her bed by her mother died four days after she was vaccinated ...